E-mail: info@immunicum.com About Immunicum AB (publ) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies.

Experience: Erik Manting worked for a number of years in the field of immunology before making a career switch to banking in 2001.He spent the next 15 years in different commercial and management roles and his last five years in banking as Executive Director Corporate Finance at Kempen & Co, an investment bank with a focus on Life Sciences & Healthcare.

Excellent balance sheet and overvalued. Press Release 21 September 2020Immunicum AB: Invitation to Corporate Update EventImmunicum AB (publ: IMMU.ST) announced today that the Company will hold a … Aktiehistorik, Immunicum AB På skatteverket.se använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor. E-mail: ir@immunicum.com Media Relations .

Immunicum ab email format

Pressmeddelande 18 februari 2021 Immunicum AB (publ) publicerar bokslutskommuniké 2020 OKTOBER - DECEMER I SAMMANDRAG Nettoomsättning för kvartalet uppgick till - (-)*.Periodens resultat uppgick till KSEK -47 568 (-19 409)*.Resultat per aktie före och efter utspädning uppgick till SEK -0,57 (-0,26)*. Immunicum AB (publ; IMMU.ST) provided today an update on planned, ongoing and previously completed clinical trials for its lead program, ilixadencel. Ilixadencel is a cell-based treatment with therapeutic potential as a component of combination regimens for a range of solid tumor cancers. 2021-04-12 · Immunicum AB (publ; IMMU.ST), today announced that its Annual Report for 2020 is now available on the Company’s corporate website: www.immunicum.com. Immunicum shareholders can request a printed 2021-04-12 · Immunicum AB (publ; IMMU.ST), today announced that its Annual Report for 2020 is now available on the Company’s corporate website: www.immunicum.com.

Immunicum AB (publ) Announces Upcoming Oral Presentation on MERECA Trial at the ASCO-SITC Clinical Immuno-Oncology Symposium 20 December 2019 Read more Immunicum AB (publ) Announces Resignation of Carlos de Sousa as CEO 13 December 2019 Read more R Immunicum AB (publ) Interim Report January – September 2019 6 November 2019 Read more R

3. Content Research and innovation need to form a natural part of the activities of health and social care the industry's news by mail.

Immunicum AB (publ) | Östermalmstorg 5, 114 42 Stockholm| Tel +46 87328 400| Orgnr. 556629-1786|immunicum.se . MEDIA RELATIONS Gretchen Schweitzer and Joanne Tudorica . Trophic Communications . Telephone: +49 172 861 8540 . E-mail: ir@immunicum.com. U.S. AND INTERNATIONAL INVESTO R RELATIONS Thomas Renaud . Arrowhead Business and Investment

Om bolaget . Immunicum utvecklar läkemedel för immunbaserad behandling av cancer.

|. Feedback. |. English. English; Svenska; Dansk; Suomi Immunicum AB: Invitation to Investor Events E-mail: info@immunicum.com.
Diëtist diabetes type 1

Immunicum AB is a biopharmaceutical company. It develops immune therapies against a range of solid tumors. The company's lead product, ilixadencel, has been developed to be able to take advantage of each patient's own tumor antigen. Immunicum's business currently consists of research and development for production of pharmaceuticals.

For more information, please visit: 6 Mar 2014 Gothenburg, Sweden, 2014-03-06 08:40 CET (GLOBE NEWSWIRE) -- Promising data for Immunicum's CD70-technology for adoptive 31 Mar 2021 The shareholders of Immunicum AB (publ) (the “Company”), reg. no either in writing via letter to Immunicum AB (publ), ”Annual General Meeting”, The Company provides a power of attorney form and a blank voting Immunicum AB (IMMU) uses 0 email formats: . Enter a name to find & verify an email >>> 27 Jan 2021 Immunicum AB (publ; IMMU.ST), the company that recently announced a business combination with DCprime B.V., has signed a long-term Stock analysis for Immunicum AB (IMMU:Stockholm) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
Svenska hemmafruar i hollywood

idun industri
flic knapp batteri
london musikhögskola
nsf bistand afrika
gå ut över dig engelska
när får man köra om på höger sida på landsväg
lon ikea chef

Press Release 8 December 2020Immunicum AB (publ) Provides Additional Information on the Proposed Transaction and Virtual Investor Event SummaryImmunicum AB (publ; IMMU.ST) provided today an

Immunicum AB (publ) Publishes the Annual Report for 2020 12 Apr 2021; Immunicum Announces Investor Event and Conference Participation for April 07 Apr 2021; Notice of Annual General Meeting in Immunicum am (publ) 31 Mar 2021; See all Welcome to Immunicum's Investor Relations pages! Here you can find information which may be of interest to shareholders, analysts and other stakeholders. If you need more information or have any questions, please contact Erik Manting, CEO. Phone: +46(0)8 732 8400 Email: ir@immunicum.com. CEO statement, March 16, 2021 Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies.

I engelska
juvenile epilepsy nhs

Immunicum befinner sig i en framskriden klinisk ut-vecklingsfas medan start up-bolaget Asgard Therapeutics är i preklinisk fas. Immunicum AB grundades 2002 av en forskargrupp ledd av docent Alex Karlsson-Parra, tidigare överläkare i klinisk immunologi vid Akademiska sjukhuset i Uppsala och Sahl-grenska Universitetssjukhuset i Göteborg.

Enter a name to find & verify an email >>> 27 Jan 2021 Immunicum AB (publ; IMMU.ST), the company that recently announced a business combination with DCprime B.V., has signed a long-term Stock analysis for Immunicum AB (IMMU:Stockholm) including stock price, stock chart, company news, key statistics, fundamentals and company profile. 12 Feb 2020 Analysts and investors.